Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.59 |
| ▸ | PTGDR | Q13258 | 6/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2188324 | 1.00 | PTGDR2 (0.59) | PTGDR2PTGDRCYP2C9CYP3A4TBXA2R | |
| SCHEMBL2189439 | 0.86 | PTGDR2 (0.69) | PTGDR2PTGDRCYP2C9CYP3A4TBXA2R | |
| SCHEMBL2188039 | 0.86 | PTGDR2 (0.59) | PTGDR2PTGDRCYP2C9CYP3A4 | |
| SCHEMBL2190719 | 0.85 | PTGDR2 (0.61) | PTGDR2PTGDRCYP2C9CYP3A4 | |
| SCHEMBL2186860 | 0.84 | PTGDR2 (0.64) | PTGDR2PTGDRCYP2C9CYP3A4 | |
| SCHEMBL2188018 | 0.83 | PTGDR2 (0.63) | PTGDR2PTGDRCYP2C9CYP3A4 | |
| SCHEMBL2183747 | 0.83 | PTGDR2 (0.66) | PTGDR2PTGDRCYP2C9CYP3A4TBXA2R | |
| SCHEMBL2188345 | 0.82 | PTGDR2 (0.62) | PTGDR2PTGDRCYP2C9CYP3A4 | |
| SCHEMBL2190664 | 0.81 | PTGDR2 (0.61) | PTGDR2PTGDRCYP2C9CYP3A4 | |
| SCHEMBL2188991 | 0.81 | PTGDR2 (0.61) | PTGDR2PTGDRCYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637671-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK CANADA INC. (CA) | 2014-01-28 | — | — | US | claimed |
| US-20110172263-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD (CA) | 2011-07-14 | — | — | US | claimed |
| EP-2346865-B1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK CANADA INC (CA) | 2015-07-15 | — | — | EP | disclosed |
| US-8637671-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK CANADA INC. (CA) | 2014-01-28 | — | — | US | disclosed |
| US-20110172263-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD (CA) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172263-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | PTGER2, PTGDR2, PTGDR | PTGDR2 2/4885PTGDR 3/4885CYP2C9 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.